Status:
COMPLETED
Genetic Polymorphism and OROS-Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder(ADHD)
Lead Sponsor:
Bundang CHA Hospital
Collaborating Sponsors:
Hallym University Medical Center
Conditions:
Attention Deficit Hyperactivity Disorder
Eligibility:
All Genders
6-18 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to examine whether genetic polymorphisms in drug transporters were associated with the side effects of OROS-methylphenidate medication in attention deficit/hyperactivity d...
Detailed Description
20 to 30% of children with attention deficit/hyperactivity disorder(ADHD) do not respond or could not tolerate methylphenidate treatment. Drug transporters such as multidrug resistant proteins(MDR) pl...
Eligibility Criteria
Inclusion
- ADHD
- Must be able to swallow a capsule
Exclusion
- Pervasive developmental disorder
- Mental retardation
- Psychotic disorder
- Bipolar disorder
- Suicidality
- Neurological disorder
- Concurrent psychiatric treatment
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00842127
Start Date
March 1 2006
End Date
August 1 2008
Last Update
February 12 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bundang CHA hospital
Seongnam, Kyonggi-do, South Korea, 463-712